Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us now| Characteristic | 2015 | 2017 | 2019 |
|---|---|---|---|
| Diphtheria | 95.3% | 93.6% | 92.7% |
| Tetanus | 95.5% | 93.8% | 92.9% |
| Whooping cough | 94.9% | 93.2% | 92.4% |
| Haemophilius influenzae type B (Hib) | 93.3% | 91.6% | 91% |
| Poliomyelitis (IPV) | 94.5% | 92.9% | 92.3% |
| Hepatitis B | 87.6% | 86.9% | 87.4% |
| Measles, dose 1 | 96.8% | 97.1% | 97.2% |
| Measles, dose 2 | 92.8% | 92.8% | 92.7% |
| Mumps, dose 1 | 96.5% | 96.9% | 97% |
| Mumps, dose 2 | 92.6% | 92.6% | 92.6% |
| Rubella 1st dose | 96.5% | 96.9% | 97% |
| Rubella 2nd dose | 92.6% | 92.6% | 92.6% |
| Varicella 1st dose | 87.1% | 87.3% | 88.9% |
| Varicella 2nd dose | 83.7% | 83.7% | 85% |
| Tick-borne encephalitis | 24.6% | 23.9% | - |
| Meningococcus C | 89.3% | 89.5% | 90.1% |
| Pneumococcus | 86.1% | 83.8% | 83.4% |
| Rotavirus | 32.8% | - | 34.5% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Source
Release date
October 2022
More information
Region
Germany
Survey time period
2015 to 2019
Citation formats
